Ken Fisher Celldex Therapeutics, Inc. Transaction History

Fisher Asset Management, LLC

$227 Billion
Q1 2025

A detailed history of Ken Fisher (Fisher Asset Management, LLC) transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Fisher Asset Management, LLC holds 871,628 shares of CLDX stock, worth $16.3 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

871,628

Previous 452,497 92.63%

Holding current value

$16.3 Million

Previous $11.4 Million 38.36%

% of portfolio

0.01%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 14, 2025	BUY	$18.15 - $27.6 $7.61 Million - $11.6 Million	419,131 Added 92.63%	871,628 $15.8 Million
Q4 2024 Feb 05, 2025	BUY	$23.31 - $32.4 $1.82 Million - $2.53 Million	78,145 Added 20.87%	452,497 $11.4 Million
Q3 2024 Nov 12, 2024	BUY	$32.06 - $44.56 $8.14 Million - $11.3 Million	253,808 Added 210.55%	374,352 $12.7 Million
Q2 2024 Aug 14, 2024	SELL	$32.76 - $42.56 $107,845 - $140,107	-3,292 Reduced 2.66%	120,544 $4.46 Million
Q1 2024 May 09, 2024	BUY	$35.22 - $51.88 $3.59 Million - $5.29 Million	102,024 Added 467.74%	123,836 $5.2 Million
Q4 2023 Mar 05, 2024	BUY	$22.61 - $40.65 $7,235 - $13,008	320 Added 1.49%	21,812 $865,000
Q4 2023 Feb 06, 2024	BUY	$22.61 - $40.65 $21,569 - $38,780	954 Added 4.65%	21,492 $852,000
Q1 2023 May 01, 2023	SELL	$34.78 - $47.43 $294,899 - $402,158	-8,479 Reduced 29.22%	20,538 $739,000
Q4 2022 Feb 03, 2023	SELL	$27.78 - $45.38 $135,455 - $221,272	-4,876 Reduced 14.39%	29,017 $1.29 Million
Q3 2022 Nov 08, 2022	BUY	$22.7 - $37.57 $769,371 - $1.27 Million	33,893 New	33,893 $953,000

Others Institutions Holding CLDX

# of Institutions

188

Shares Held

69.3M

Call Options Held

220K

Put Options Held

310K

View Full List

About Celldex Therapeutics, Inc.

Ticker CLDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,772,400
Market Cap $873M
Description
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...

More about CLDX

Track Ken Fisher's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fisher Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fisher Asset Management, LLC and Ken Fisher with notifications on news.

Account